A Model Built to Solve a Problem the Industry Kept Recreating
The site management organization did not appear out of nowhere. It was a direct response to a structural problem that the clinical research industry had spent decades making worse, and the site management organization was the solution that finally stuck.
For most of the twentieth century, clinical trials lived almost exclusively inside academic medical centers. Large universities, major hospital systems, specialized research institutions were the gatekeepers of clinical research. If you were a pharmaceutical sponsor trying to run a study, you went where the investigators were. And the investigators were in places most patients were not.
Seventy percent of the U.S. population lives more than two hours away from the closest academic medical center. That number alone tells you everything about why the traditional model had a ceiling. The patients who participated in clinical research were largely the ones who could afford the time, the travel, and the access. Everyone else stayed home.
By the 1980s, the pressure was building from every direction. Drug development costs were rising, regulatory complexity was increasing, and sponsors needed to run more trials at more sites with more consistency than any single academic institution could provide. Something had to change.
How the Site Management Organization Changed Everything
The site management organization emerged as the industry’s answer. Rather than relying on a handful of academic centers to manage everything internally, sponsors could now work with specialized organizations that knew how to set up, staff, coordinate, and run clinical trial sites at scale.
The early site management organizations were mostly regional. They brought coordinators, regulatory expertise, operational processes, and recruitment support to sites that had investigators but lacked the infrastructure to run trials efficiently on their own. It was a simple value proposition and it worked. Sponsors got faster startups and more consistent site performance. Investigators got support without having to build a research operation from scratch.
Over the years, site management organizations evolved from small, regionally focused entities into large organizations with networks of clinical trial sites, driven by the need for faster patient recruitment, improved data quality, and enhanced regulatory compliance.
That consolidation accelerated through the 2000s and into the 2010s. Individual SMOs merged, built larger portfolios, and began operating as clinical research site networks, with dozens of dedicated locations running under centralized management, shared technology, and unified quality standards. The model had gone from a regional service provider to a sophisticated scaled platform.
But something fundamental had not changed. The dedicated research site, no matter how well run, was still a place patients had to come to. And most patients, for reasons of geography, schedule, language, economics, or simple trust, were not coming.
The Moment the Model Had to Go Inside
One strategy that had not been scaled in a sustainable way was engaging community clinicians in research. There is considerable evidence that clinician recommendations play an important role in helping patients consider participating in clinical trials, yet such engagement was not widespread. Multiple barriers impede clinician engagement in research, starting with a lack of awareness about clinical research among clinicians not affiliated with large academic medical centers.
That insight reframed the entire problem. The bottleneck was not that patients refused to participate. Less than 8% of patients with cancer participate in clinical trials, even though more than 50% will participate when offered the opportunity. The bottleneck was that the opportunity was never reaching them through the people they trusted most: their own doctors.
This realization gave rise to the Integrated Research Organization, or IRO. Instead of building a research site and waiting for patients to arrive, the IRO went inside existing healthcare settings and embedded the full clinical trial infrastructure directly into physician practices and health systems. The investigators were already there. The patient relationships were already there. The IRO brought the regulatory support, the coordinators, the data management, and the sponsor contracting infrastructure, and built a research program around what the practice already had.
The IRO model was a meaningful leap forward. It brought research closer to where patients lived and made it possible for community physicians to offer clinical trial participation as a genuine care option rather than a referral to somewhere unfamiliar. But even the IRO was still a variation on the site management organization concept, adding access without changing the underlying structure of how research networks are built.
When Embedded Stops Being a Feature and Becomes the Foundation
The Embedded Research Organization, or ERO, takes the logic of the IRO and builds it into the architecture of the organization itself rather than treating it as a service layer added onto an existing practice.
In the ERO model, the community physician is not a partner the organization works alongside. The community physician is a principal investigator operating within a network specifically designed to function at the point of care from the beginning. Research is not embedded into the practice. The practice is research, built that way on purpose.
FOMAT Medical Research has operated on this model for more than a decade, conducting Phase I through Phase IV studies through a national network of community based investigator sites across multiple therapeutic areas. In 2026, FOMAT expanded to more than 35 sites across six states, bringing that infrastructure to a broader range of communities and deepening access for the patient populations clinical research has historically underserved.
The distinction matters for sponsors and CROs because it changes what consistent performance actually means. A site management organization delivers operational consistency. An IRO delivers access through existing relationships. An ERO delivers both, because the network was never designed to separate them.
The Through Line
Every iteration of the site management organization has been trying to answer the same question: how do you get clinical research to the patients who need it, through the providers they trust, at a scale that actually moves the needle?
The SMO answered part of it. The IRO answered more. The ERO is the model that treats community based, diverse, high quality clinical research not as an aspiration but as the operating standard.
Interested in how FOMAT’s embedded research model works for sponsors and CROs? Contact our team to learn how we work.